Literature DB >> 29900975

A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis.

Hong Wang1,2, Yi-le Ren3, Jun Chang4, Luo Gu5, Ling-Yun Sun1.   

Abstract

OBJECTIVES: This study aims to conduct a meta-analysis to clarify the epidemiologic characteristics of biopsy-proven lupus nephritis (BPLN), including those relating to its prevalence and prognosis. PATIENTS AND METHODS: A literature search for relevant studies was conducted in the electronic databases of PubMed, Google Scholar, Embase, and Cochrane trial register. The following search terms were used for original articles published between January 1982 and April 2016: "lupus nephritis" or systemic lupus erythematosus ('SLE') or 'systemic lupus erythematous' and "pathology" or 'epidemiology' or prevalence or incidence. Pooled estimates with 95% confidence intervals were calculated.
RESULTS: Nineteen studies were included (mean age of SLE patients at renal biopsy: ~30 years). Of total BPLN patients, 85% were females. BPLN developed in 29% of SLE patients, and accounted for 60% of secondary glomerular diseases in renal biopsy databases. BPLN prevalence among SLE patients was higher in Saudi Arabia compared with pooled Europe/USA data (43% vs 26%, p<0.05). Pooled BPLN prevalence among secondary glomerular diseases patients was higher in Asian/Latin American countries than in Europe (63% vs 34%, p<0.05). Overall five-, 10- and 20-year survival rates of BPLN patients were 94%, 86%, and 71%, respectively, which were higher than those before 1995 (84%, 72%, and 52%, respectively) and lower than those after 1995 (96%, 89%, and 80%, respectively) (all p<0.05). Class IV nephritis, present in 40% of BPLN patients, was a risk factor for renal failure that contributed to poor prognosis.
CONCLUSION: Lupus nephritis is a common complication of young female patients with SLE, and the most prevalent etiology of secondary glomerular diseases. Attention should be paid to class IV nephritis due to its high frequency and association with poor prognosis.

Entities:  

Keywords:  Biopsy-proven lupus nephritis; epidemiology; meta-analysis

Year:  2017        PMID: 29900975      PMCID: PMC5864167          DOI: 10.5606/ArchRheumatol.2017.6127

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  35 in total

1.  Retrospective analysis of patients with lupus nephritis: data from a large clinical immunological center in Hungary.

Authors:  B Brugos; E Kiss; P Szodoray; G Szegedi; M Zeher
Journal:  Scand J Immunol       Date:  2006-10       Impact factor: 3.487

2.  The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient.

Authors:  Mumtaz Patel; Alexandra M Clarke; Ian N Bruce; Deborah P M Symmons
Journal:  Arthritis Rheum       Date:  2006-09

Review 3.  Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management.

Authors:  Giulio Fortuna; Michael T Brennan
Journal:  Dent Clin North Am       Date:  2013-10

4.  Cardiovascular and cerebrovascular morbidity and mortality among women with end-stage renal disease attributable to lupus nephritis.

Authors:  M M Ward
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

5.  The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese.

Authors:  Hitoshi Yokoyama; Takashi Wada; Akinori Hara; Junya Yamahana; Izaya Nakaya; Motoo Kobayashi; Kiyoki Kitagawa; Satoshi Kokubo; Yasunori Iwata; Keiichi Yoshimoto; Kazuaki Shimizu; Norihiko Sakai; Kengo Furuichi
Journal:  Kidney Int       Date:  2004-12       Impact factor: 10.612

Review 6.  [Class IV-G and IV-S lupus nephritis, interstitial infiltrates and prognosis: state of the art and unmet medical needs].

Authors:  Gianfranco Ferraccioli; Elisa Gremese
Journal:  G Ital Nefrol       Date:  2012 Nov-Dec

Review 7.  Current management of lupus nephritis.

Authors:  Frédéric A Houssiau; Bernard R Lauwerys
Journal:  Best Pract Res Clin Rheumatol       Date:  2013-06       Impact factor: 4.098

8.  Glomerular diseases in a Hispanic population: review of a regional renal biopsy database.

Authors:  Luis Fernando Arias; Jorge Henao; Rubén Darío Giraldo; Nelson Carvajal; Joaquin Rodelo; Mario Arbeláez
Journal:  Sao Paulo Med J       Date:  2009       Impact factor: 1.044

Review 9.  The pathogenesis of lupus nephritis.

Authors:  Maciej Lech; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2013-08-08       Impact factor: 10.121

10.  Percutaneous renal biopsy results: a retrospective analysis of 511 consecutive cases.

Authors:  Malik Anas Rabbani; Ghulam Murtaza Memon; Bushra Ahmad; Shehla Memon; Syeda Anjala Tahir; Shumaila Tahir
Journal:  Saudi J Kidney Dis Transpl       Date:  2012-05
View more
  11 in total

Review 1.  Lupus Nephritis: Improving Treatment Options.

Authors:  Myrto Kostopoulou; Sofia Pitsigavdaki; George Bertsias
Journal:  Drugs       Date:  2022-04-29       Impact factor: 9.546

Review 2.  Treat-to-target in systemic lupus erythematosus: advancing towards its implementation.

Authors:  Agner R Parra Sánchez; Alexandre E Voskuyl; Ronald F van Vollenhoven
Journal:  Nat Rev Rheumatol       Date:  2022-01-17       Impact factor: 20.543

3.  Spectrum of Morphological and Immunofluorescence Patterns in Lupus Nephritis: A Single Institutional Study.

Authors:  Saira Javeed; Safana Sadaf; Saima Batool; Ayma Batool; Zubaria Rafique; Akhtar S Chughtai
Journal:  Cureus       Date:  2022-05-26

Review 4.  Tailored treatment strategies and future directions in systemic lupus erythematosus.

Authors:  Dionysis Nikolopoulos; Lampros Fotis; Ourania Gioti; Antonis Fanouriakis
Journal:  Rheumatol Int       Date:  2022-04-21       Impact factor: 3.580

5.  Glomerulonephritis Histopathological Pattern Change.

Authors:  Anas AlYousef; Ali AlSahow; Bassam AlHelal; Ahmed Alqallaf; Emad Abdallah; Mohammed Abdellatif; Hani Nawar; Riham Elmahalawy
Journal:  BMC Nephrol       Date:  2020-05-18       Impact factor: 2.388

Review 6.  Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.

Authors:  Marion Ort; Jasper Dingemanse; John van den Anker; Priska Kaufmann
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 7.561

7.  Vasculature-Associated Lymphoid Tissue: A Unique Tertiary Lymphoid Tissue Correlates With Renal Lesions in Lupus Nephritis Mouse Model.

Authors:  Md Abdul Masum; Osamu Ichii; Yaser Hosny Ali Elewa; Yuki Otani; Takashi Namba; Yasuhiro Kon
Journal:  Front Immunol       Date:  2020-12-15       Impact factor: 7.561

Review 8.  Management of Lupus Nephritis.

Authors:  Farah Tamirou; Frédéric A Houssiau
Journal:  J Clin Med       Date:  2021-02-09       Impact factor: 4.241

9.  Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.

Authors:  David Jayne; Brad Rovin; Eduardo F Mysler; Richard A Furie; Frederic A Houssiau; Teodora Trasieva; Jacob Knagenhjelm; Erik Schwetje; Yen Lin Chia; Raj Tummala; Catharina Lindholm
Journal:  Ann Rheum Dis       Date:  2022-02-10       Impact factor: 27.973

10.  Silent Lupus Nephritis: Renal Histopathological Profile and Early Detection with Urinary Monocyte Chemotactic Protein 1.

Authors:  Wesam Gouda; Aldosoky Abd Elaziz Alsaid; Awad Saad Abbas; Tarek M Abdel-Aziz; Mohamed Z Shoaeir; Abd Allah S Abd Elazem; Mohammad Hamdy Sayed
Journal:  Open Access Rheumatol       Date:  2022-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.